BRIEF published on 06/17/2025 at 20:35, 1 year 4 months ago L'Assemblée Générale de GENFIT approuve les résolutions du Conseil d'Administration Resolutions Produits Biopharmaceutiques Assemblée Générale Des Actionnaires GENFIT Maladies Du Foie
BRIEF published on 06/17/2025 at 20:35, 1 year 4 months ago GENFIT's Shareholder Meeting Approves Board's Resolutions Biopharmaceuticals Resolutions Liver Diseases Shareholders Meeting GENFIT
PRESS RELEASE published on 06/17/2025 at 20:30, 1 year 4 months ago GENFIT : Résultats de l’Assemblée Générale Mixte du 17 juin 2025 GENFIT annonce les résultats de son Assemblée Générale Mixte du 17 juin 2025, approuvés avec un quorum de 27,21%, tout en dévoilant sa mission et activités dans le secteur biopharmaceutique Biopharmaceutique Assemblée Générale Mixte Maladies Rares GENFIT Foie
PRESS RELEASE published on 06/17/2025 at 20:30, 1 year 4 months ago GENFIT: June 17, 2025 Combined Shareholders Meeting Results GENFIT announces approval of all resolutions at June 17, 2025 Combined Shareholders Meeting. Exception: resolution n°28 rejected. Quorum: 27.21% Resolutions Approval Quorum Shareholders Meeting GENFIT
BRIEF published on 05/22/2025 at 22:15, 1 year 5 months ago GENFIT : Résultats financiers du premier trimestre 2025 Trésorerie Royalties GENFIT Iqirvo® Phase Clinique
BRIEF published on 05/22/2025 at 22:15, 1 year 5 months ago GENFIT: First Quarter 2025 Financial Results Treasury Royalties GENFIT Iqirvo® Clinical Phase
PRESS RELEASE published on 05/22/2025 at 22:10, 1 year 5 months ago GENFIT : Information financière du premier trimestre 2025 GENFIT annonce sa position de trésorerie au 31 mars 2025 et son chiffre d’affaires pour le premier trimestre 2025. L'entreprise évolue dans le domaine des maladies rares du foie Chiffre D'affaires Trésorerie Maladies Rares GENFIT Foie
PRESS RELEASE published on 05/22/2025 at 22:10, 1 year 5 months ago GENFIT Reports First Quarter 2025 Financial Information GENFIT reports Q1 2025 financial information showing cash position growth and revenue increase. Details on Royalty Financing agreement, research efforts, and corporate governance update included Financial Information Revenue Cash Position GENFIT Q1 2025
BRIEF published on 05/20/2025 at 22:15, 1 year 5 months ago GENFIT receives €26.5 million following a key milestone in Italy Italy Primary Biliary Cholangitis GENFIT Milestone Payment Iqirvo®
BRIEF published on 05/20/2025 at 22:15, 1 year 5 months ago GENFIT reçoit 26,5 millions d'euros suite à une étape clé en Italie Italie Cholangite Biliaire Primitive GENFIT Iqirvo® Versament D'étape
Published on 10/30/2026 at 23:35, 1 day 19 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 1 day 20 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 2 days ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 2 days 4 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/01/2026 at 10:35, 8 hours 56 minutes ago Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video
Published on 11/01/2026 at 05:00, 14 hours 31 minutes ago 2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu
Published on 10/31/2026 at 16:35, 1 day 2 hours ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 1 day 20 hours ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 23:00, 1 day 20 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 23:00, 1 day 20 hours ago Biophytis publie les résultats du premier semestre 2026 et fait le point sur sa stratégie
